Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 8, 2013, Pages 645-651

  Leutscher, Peter Derek Christian ^a   Stecher, Chalotte ^a   Storgaard, Merete ^a   Larsen, Carsten Schade ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Drug discontinuation; Efavirenz; HIV; Neuropsychiatric adverse effects

Indexed keywords

EFAVIRENZ;

ABNORMAL DREAMING; ADULT; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; DIZZINESS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DISEASE; MOOD CHANGE; NEUROLOGIC DISEASE; QUALITY OF LIFE; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MENTAL DISORDERS; WITHHOLDING TREATMENT;

EID: 84880291960     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.773067     Document Type: Article

References (20)

1. European AIDS Clinical Society (EACS) guidelines. Version 6. EACS;2011.
2. Pérez-Molina J A. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002;3:279-86.
3. Fumaz CR, Tuldr à A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defi c Syndr 2002;29:244-53. (Pubitemid 34208532)
4. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143:714-21.
5. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. Treatment modifi cation in human immunedefi ciency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57-65.
6. Dalgaard L, Soegaard OS, Jensen-Fangel S, Larsen CS, Sön-nerborg A, Estergaard L. Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study. Scand J Infect Dis 2012;44:108-14.
7. Fumaz C R, Munoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acquir Immune Defi c Syndr 2005;38:560-5. (Pubitemid 40524478)
8. Rihs T A, Begley K, Smith DE, Sarangapany J, Callaghan A, Kelly M, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006;7:544-8. (Pubitemid 44742355)
9. Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother 2007;8:851-7.
10. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM;A5097s Study Team. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009;10:343-55.
11. Gutié rrez F, Navarro A, Padillo S, Antón R, Masiá M, Borrá s J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41:1648-53. (Pubitemid 41691605)
12. Gatanaga H, Hayashida T, Tsuchiiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and*26. Clin Infect Dis 2007;45:1230-7. (Pubitemid 47580326)
13. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profi les. AIDS Patient Care STDS 2006;20:542-8. (Pubitemid 44769201)
14. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-na ï ve patients: a systematic review. AIDS Rev 2010:12:67-75.
15. Waters L, Fischer M, Winston A, Higgs C, Hadley C, Garvey L, et al. Aphase IV, double-blind, multicentre, randomized, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011;25:65-71.
16. Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, et al. Arandomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011;25:57-63.
17. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Pilpivirine versus efavirenz and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-46.
18. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two backbone nucleoside or nucleotide reverse transcriptase inhibitors in treatment-na ï ve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-37.
19. Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, et al. Acomparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011;25:335-40.
20. Petersen T, Andersen SE, Gerstoft J, Thorsteinsson K, Larsen CS, Pedersen G, et al. Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study. Br J Clin Pharmacol 2011;72:116-24.